IDEXX Laboratories (IDXX) Expected to Announce Earnings on Monday

IDEXX Laboratories (NASDAQ:IDXX) is expected to be issuing its Q4 2025 results before the market opens on Monday, February 2nd. Analysts expect the company to announce earnings of $2.93 per share and revenue of $1.0723 billion for the quarter. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, February 2, 2026 at 8:30 AM ET.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The firm had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the business earned $2.80 EPS. The firm’s revenue for the quarter was up 13.3% on a year-over-year basis. On average, analysts expect IDEXX Laboratories to post $12 EPS for the current fiscal year and $14 EPS for the next fiscal year.

IDEXX Laboratories Trading Down 0.9%

IDEXX Laboratories stock opened at $670.46 on Friday. The stock has a 50-day moving average of $705.35 and a two-hundred day moving average of $660.81. The stock has a market cap of $53.54 billion, a PE ratio of 53.17, a price-to-earnings-growth ratio of 3.61 and a beta of 1.67. IDEXX Laboratories has a one year low of $356.14 and a one year high of $769.98. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.87 and a current ratio of 1.18.

Analyst Ratings Changes

A number of equities analysts recently weighed in on IDXX shares. BTIG Research upped their price target on IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Stifel Nicolaus set a $775.00 price objective on IDEXX Laboratories in a research report on Monday, November 3rd. Barclays initiated coverage on IDEXX Laboratories in a research note on Monday, December 8th. They set an “overweight” rating and a $850.00 target price for the company. UBS Group lifted their price target on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Finally, Wall Street Zen cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 17th. Seven research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $763.50.

Insider Activity

In other news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the sale, the executive vice president directly owned 21,149 shares in the company, valued at $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.98% of the stock is owned by insiders.

Institutional Trading of IDEXX Laboratories

Several large investors have recently bought and sold shares of the business. Sivia Capital Partners LLC purchased a new position in shares of IDEXX Laboratories during the 2nd quarter worth $265,000. Eisler Capital Management Ltd. acquired a new stake in IDEXX Laboratories during the third quarter worth about $204,000. SeaCrest Wealth Management LLC purchased a new position in IDEXX Laboratories during the third quarter worth about $214,000. State of Wyoming boosted its holdings in IDEXX Laboratories by 143.3% in the 2nd quarter. State of Wyoming now owns 382 shares of the company’s stock valued at $205,000 after purchasing an additional 225 shares during the last quarter. Finally, Geneos Wealth Management Inc. boosted its holdings in IDEXX Laboratories by 16.6% in the 2nd quarter. Geneos Wealth Management Inc. now owns 379 shares of the company’s stock valued at $203,000 after purchasing an additional 54 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.